Two molecules may provide, for the first time, an indication of which stroke patients will suffer a further, long-term neurological deficit, allowing doctors to tailor treatment more effectively.
By discovering how a blood clot-busting enzyme is switched on, researchers have unlocked a century-old atomic riddle that could lead to new treatments for clotting and bleeding disorders, and some cancers.